Results-From-the-Phase-3-NRG-RTOG-1112-Study-of-Sorafenib-in-HCC-Targeted-Oncology-hatinco.com の変更点

追加された行はこの色です。
削除された行はこの色です。
Results-From-the-Phase-3-NRG-RTOG-1112-Study-of-Sorafenib-in-HCC-Targeted-Oncology-hatinco.com へ行く。
Results-From-the-Phase-3-NRG-RTOG-1112-Study-of-Sorafenib-in-HCC-Targeted-Oncology-hatinco.com の差分を削除


#author("2023-01-21T07:02:03+09:00","","")
Results From the Phase 3 NRG/RTOG 1112 Study of Sorafenib in HCC - Targeted Oncology
Laura A. Dawson, MD, FRCPC, discusses findings from the NRG/RTOG 1112 study of stereotactic body radiation therapy followed by sorafenib vs sorafenib alone in hepatocellular carcinoma.
Author : Laura Dawson, MD
#technology #tech #innovation #engineering #business #iphone #technews #science #design #apple #gadgets #electronics #android #programming #software #smartphone #samsung #instagood #coding #computer #pro #instatech #education #security #gadget #mobile #instagram #technologynews #HATINC
READ MORE : https://hatinco.com/results-from-the-phase-3-nrg-rtog-1112-study-of-sorafenib-in-hcc.htm